Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Discontinuation of first-line DMT in long-term full responders with relapsing-remitting multiple sclerosis
2016-004819-12Phase 4Terminated
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jan 2022
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of interferon beta-1a, interferon beta-1b and glatiramer acetate in multiple sclerosis (MS) (2 arms), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Proportion of patients free from disease activity at two years. Started Jan 2022; status: terminated.
02
Drugs
interferon beta-1ainterferon beta-1bglatiramer acetate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2016-004819-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004819-12.